![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, July 16, 2021 9:38:12 AM
...let's assume for purposes of discussion that both 2-73 and 1066 will be megablockbuster drugs. How could you account for one tiny company coming up with two such pharmaceuticals? The odds against just one are unreal.
And they haven’t known or seen anything useful at the sigma-1 receptor protein. First, its innate functions and mechanisms of action were until recently unknown, unrecognized. Just a nice little protein lodged between the mitochondrion and the attached endoplasmic reticulum. Should anyone want to look around (inside any cell, but particularly in neurons), there are hundreds of distinct proteins. No one at any of the other pharmaceuticals had any reason to scrutinize the sigma-1 receptor protein.
And, even if they did, they had no molecules that could in any usefully way affect it.
So, as with most of everything else useful in medical science, with Anavex there has been “new science,” things that at the start appear pretty nebulous and without probable application. Every field of science experiences this, but particularly medicine.
Classically, take the “germ theory,” the strange and weird notion (back then) that some sort of invisible “microbes” are the actual cause of many diseases. These “germs” (disease-producers) can move into organisms and produce all sorts of diseases. Of course, medical science utterly rejected this, for decades. Pasteur, Lister, and a few others finally won the argument, but only after “the real professionals” for decades rejected the scientific evidence.
Check the grief and push-back Semmelwiess got for decades trying to keep microbes from mothers during delivery:
https://en.wikipedia.org/wiki/Ignaz_Semmelweis
Scientists don’t like to have their bodies of knowledge discarded, or even questioned. The germ theory did that. In physics, Einstein disrupted things profoundly.
(Currently, I’m working with a university research team in my particular area of ecological science, where we are, similar to Anavex, developing very new ecological techniques and protocols that will solve a major ecological problem. Implementation will take a few more years; in the mean time we’ve had to convince intelligent sceptics that our stuff really works. “Hard to believe!” New ecological science; being rejected for now. Later, broad applications and understandings.)
So, why and how Anavex science? Because a few people had the vision to see that their unique, proprietary molecules could produce wonderful therapeutic (even prophylactic) outcomes. All of that went against what was known about, say, Parkinson’s and Alzheimer’s diseases. Before, no one knew how the sigma-1 receptor protein actually worked, or what it caused to happen in cells. Now, Anavex knows, and has in-house molecules that modulate and promote the multiple functions of the sigma-1 receptor.
There will be blow-back (understood), but I’ll make the claim now: In time, a Nobel Prize or two will be awarded to those at Anavex who have been instrumental in bring forth Anavex science. In the last century antibiotics changed medicine profoundly. In the 21st century, Anavex will make probably even greater improvements — all because a few individuals were not restrained by conventional understandings or practice. Like all great scientists, they could look beyond what is known and accepted, seeing new things that needed to be studied and perfected.
Why Anavex? Scientific brilliance, unconstrained by conventional knowledge or perspective.
.
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM